CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Intracellular Micronutrient Panel Testing — Coverage Criteria

Policy governing coverage and medical necessity of commercial laboratory intracellular micronutrient panel testing for Blue Cross Blue Shield - Rhode Island members, including Medicare Advantage and Commercial products.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyIntracellular Micronutrient Panel Testing — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionDo not submit claims for this panel to Medicare Advantage; for Commercial Products the test is considered not medically necessary and should not be authorized.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance

No RCTsRCT evidence

≥2 labsLabs offering test

84999Claims coding

Coverage Determination

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medicare Advantage and Commercial Products coverage: Intracellular micronutrient panel testing is not covered for Medicare Advantage Plans and is not medically necessary for Commercial Products as the evidence is insufficient to determine the effects of the technology on health outcomes.

No randomized controlled trials or comparative studies identified; insufficient chain of evidence to show improved health outcomes.

Some genetic testing services exclusions and contract-specific exclusions may apply for Commercial Products. Review the member's Benefit Booklet and the Coding section of the Genetic Testing Services and Proprietary Laboratory Analyses policies to determine whether a group has customized coverage, which tests require prior authorization, or which services are not covered.

The rationale for the policy is that evidence is insufficient to demonstrate clinical validity or utility for commercial intracellular micronutrient panels. No randomized controlled trials or comparative studies were identified, and available observational data do not establish a chain of evidence showing that intracellular results improve health outcomes compared with standard serum testing. Therefore these tests are considered not medically necessary for Commercial Products.

Covered indications

Covered indications: Document does not list any covered indications for intracellular micronutrient panel testing; potential uses (screening or aiding diagnosis) are noted but no medical criteria are provided to support coverage.

Standard serum testing is the accepted approach for confirming suspected micronutrient deficiencies; intracellular testing lacks validated clinical utility.

Not Covered / Not Medically Necessary

Intracellular micronutrient panel testing is not covered for Medicare Advantage Plans and is not medically necessary for Commercial Products because the evidence is insufficient to determine effects on health outcomes. Laboratories are prohibited from obtaining authorization on behalf of the ordering physician; unauthorized services provided by a laboratory may be denied and become the financial responsibility of the laboratory.

Coding and Billing Guidance

Coding guidanceCPT

84999

Unlisted chemistry procedure; used for filing this panel as there is no specific CPT code

Panel coding rule — do not report with specific CPT codes for each element

Panel coding ruleClaims for this intracellular micronutrient panel should not be reported using the specific CPT codes for each individual element of the panel; file using the unlisted CPT code 84999 when submitting claims.

RationaleNo specific CPT code exists for the full panel; the policy explicitly instructs not to report component CPTs.

Billing noteUse CPT 84999 (unlisted chemistry procedure) for claim submission for this panel.

Provider Requirements and Billing Risks

Prior Authorization

Prior Authorization: Not applicable.

Prior auth not required for this testing.

Denial Risk

Coverage and Medical Necessity

Intracellular micronutrient panel testing is not covered for Medicare Advantage Plans and is considered not medically necessary for Commercial Products. Evidence is insufficient to support clinical benefit.

Documentation Required

Authorization Responsibility

Only the ordering physician may initiate and participate in authorization, appeal, or other administrative processes related to prior authorization and medical necessity. Laboratories are not permitted to obtain clinical authorization or act on behalf of the ordering physician.

Ordering physician must handle all authorization and appeal activities.
Laboratories and their representatives may not obtain authorizations or submit appeals on behalf of the ordering physician.

Denial Risk

Prohibition on Laboratory Involvement

If a laboratory or third party supports or facilitates any portion of the authorization process on behalf of an ordering physician, BCBSRI will consider this a violation and may take severe actions up to termination from the BCBSRI provider network.

Such violations include preparation or submission of documentation for authorization or appeals by laboratories or their representatives.

Billing Rule

Laboratory Billing Risk

If a laboratory provides services that were not authorized, those services will be denied and the financial liability will rest with the participating laboratory; such services may not be billed to the member.

Unauthorized laboratory services denied as financial liability of the lab.

Clinical Background

Intracellular micronutrient testing measures intracellular levels of vitamins, minerals, antioxidants, amino acids, fatty acids or metabolites in cells (for example, lymphocytes or buccal epithelial cells) using laboratory-developed panel methods. Proponents suggest intracellular measures may better reflect long-term status than serum tests, but the relationship between serum and intracellular concentrations depends on transport mechanisms and cell type. Classic clinical micronutrient deficiencies are uncommon in the U.S., and no studies were identified that establish the clinical validity or clinical utility of intracellular testing compared with standard serum testing.

Definitions

Intracellular micronutrient testing — definition

DefinitionIntracellular micronutrient testing (also called intracellular micronutrient analysis or functional intracellular analysis): laboratory-developed panels measuring intracellular levels of vitamins, minerals, antioxidants, amino acids, fatty acids, or metabolites in cells such as lymphocytes or buccal epithelial cells.

Typical analytes measuredVitamins (A, B1, B2, B3, B6, B12, C, D, K, biotin, folate, pantothenic acid), minerals (calcium, magnesium, zinc, copper), antioxidants (alpha-lipoic acid, coenzyme Q10, cysteine, glutathione, selenium, vitamin E), amino acids, fatty acids, and metabolites.

Specimen types / methodsExamples include epithelial cells from buccal swabs (EXA Test) or lymphocytes from blood samples (SpectraCell).

Regulatory statusOffered as laboratory-developed tests under CLIA high-complexity standards; FDA has not required regulatory review to date.

Frequency Limits

Frequency limits (placeholder)

Frequency limitsNo frequency limits specified in the policy for intracellular micronutrient panel testing.

Covered indicationsDocument does not list any covered indications; potential uses noted (screening or aiding diagnosis) but no medical criteria provided.

Policy stanceIntracellular micronutrient panel testing is not covered for Medicare Advantage Plans and is not medically necessary for Commercial Products.

Ordering and Authorization Requirements

Step Therapy

Ordering limitation — labs may not obtain authorizations for ordering physician

Laboratories are not permitted to obtain authorizations on behalf of the ordering provider; any attempt by a lab or its representative to do so is a policy violation and may result in severe sanctions.

Labs cannot participate in or facilitate any portion of the authorization or appeal process for the ordering physician.
Violations may lead to actions including termination from the BCBSRI provider network and financial liability for denied services.

Policy Metadata and Related Policies

Scope: This policy addresses coverage and medical necessity for laboratory intracellular micronutrient panel testing for Blue Cross Blue Shield of Rhode Island members, including Medicare Advantage and Commercial products. Related policies include the Biomarker Testing Mandate, Genetic Testing Services, and Unlisted Procedures. For plan-specific exclusions or prior authorization requirements, consult the member’s Benefit Booklet and the referenced genetic testing policies.